Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders
- 19 August 2023
- journal article
- editorial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 58 (11) , 1175-1176
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching studyBone Marrow Transplantation, 2023
- Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cellsAnnals of the Rheumatic Diseases, 2023
- Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosusNature Medicine, 2022
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectivesKidney International, 2020
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2019
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaNew England Journal of Medicine, 2017
- Updated assessment of the prevalence, spectrum and case definition of autoimmune diseaseAutoimmunity Reviews, 2012
- The Risk of Lymphoma Development in Autoimmune DiseasesArchives of internal medicine (1960), 2005